Mesoblast Update – CORRECTION

Last week I wrote a short update on the company Mesoblast [ASX:MSB]. In that update I noted that the downtrend in the stock had began after ‘after the company received disappointing results from a trial.’

That was a complete mistake on my part, and needs to be corrected. I confused two different companies and wrongly attributed the disappointing trial result to Mesoblast.

The article was removed from our website as soon as I became aware of the error.

I apologise for the mistake.

Callum Newman
Editor, Markets and Money

Join Markets and Money on Google+


Originally graduating with a degree in Communications, Callum decided financial markets were far more fascinating than anything Marshall McLuhan (the ‘medium is the message’) ever came up with. Today Callum spends his day reading and researching why currencies, commodities and stocks move like they do. So far he’s discovered it’s often in a way you least expect.


Leave a Reply

Your email address will not be published. Required fields are marked *

Markets & Money